| The TRAIL apoptotic pathway in cancer onset, progression and therapy | Nature Reviews Cancer | 2008 | 690 |
| Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 338 |
| Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 246 |
| DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors | Journal of Experimental Medicine | 2008 | 234 |
| IFNgamma signaling-does it mean JAK-STAT? | Cytokine and Growth Factor Reviews | 2008 | 232 |
| The MACPF/CDC family of pore-forming toxins | Cellular Microbiology | 2008 | 214 |
| Immune-mediated dormancy: an equilibrium with cancer | Journal of Leukocyte Biology | 2008 | 205 |
| Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis | Journal of Immunology | 2008 | 139 |
| Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 114 |
| Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 105 |
| Immunogenic anti-cancer chemotherapy as an emerging concept | Current Opinion in Immunology | 2008 | 86 |
| Mesenchymal stem cells in cancer | Stem Cell Reviews and Reports | 2008 | 81 |
| Histone deacetylase inhibitors in lymphoma and solid malignancies | Expert Review of Anticancer Therapy | 2008 | 78 |
| Interleukin 21: combination strategies for cancer therapy | Nature Reviews Drug Discovery | 2008 | 77 |
| Application of CD27 as a marker for distinguishing human NK cell subsets | International Immunology | 2008 | 65 |
| Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin | Molecular Cancer Therapeutics | 2008 | 58 |
| Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo | Journal of Immunology | 2008 | 56 |
| IFN-gamma-dependent recruitment of mature CD27(high) NK cells to lymph nodes primed by dendritic cells | Journal of Immunology | 2008 | 53 |
| Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis | PLoS Pathogens | 2008 | 51 |
| Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 40 |
| Cancer vaccines for established cancer: how to make them better? | Immunological Reviews | 2008 | 39 |
| Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity | Cell Death and Differentiation | 2008 | 33 |
| Granzyme K expressing cytotoxic T lymphocytes protects against influenza virus in granzyme AB-/- mice | Viral Immunology | 2008 | 31 |
| Upsides and downsides to polarity and asymmetric cell division in leukemia | Oncogene | 2008 | 27 |
| Can NK cells be a therapeutic target in human cancer? | European Journal of Immunology | 2008 | 26 |
